



#10 1724

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.

INVENTION: : APOLIPOPROTEIN BIOPOLYMER MARKER  
INDICATIVE OF NORMAL HUMAN

SERIAL NUMBER : 09/993,300

FILING DATE : November 23, 2001

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1741

ATTORNEY DOCKET NO. : 2132.107

RECEIVED  
MAR 28 2003  
TC 1700TRANSMITTAL LETTERCERTIFICATE UNDER 37 CFR 1.8(a)  
I hereby certify that this correspondence is being  
deposited with the U.S. Postal Service as First Class mail  
in an envelope addressed to Commissioner for  
Patents, Washington, D.C. 20231 on 3-20-03  
Susan IdessCommissioner for Patents  
Washington, D.C. 20231

Sir:

Please find enclosed for filing:

Supplemental Information Disclosure Statement  
 Certification Pursuant to 37 C.F.R. §1.97(e)  
 Copy of International Search Report  
 PTO-1449  
 References

RECEIVED

APR 02 2003

TECH CENTER 1600/2900

Respectfully Submitted,

Ferry H. Lander

Ferry H. Lander  
Reg. No. 43,377  
McHale & Slavin, P.A.  
4440 PGA Boulevard, Suite 402  
Palm Beach Gardens, FL 33410  
Telephone: (561) 625-6575

Date: 3-19-2003



#10

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.

INVENTION: : APOLIPOPROTEIN BIOPOLYMER MARKER  
INDICATIVE OF NORMAL HUMAN

SERIAL NUMBER : 09/993,300

FILING DATE : November 23, 2001

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1741

ATTORNEY DOCKET NO. : 2132.107

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)  
I hereby certify that this correspondence is being  
deposited with the U.S. Postal Service as First Class mail  
in an envelope addressed to Commissioner for  
Patents, Washington, D.C. 20231 on 3-20-03

Susan BessCommissioner for Patents  
Washington, D.C. 20231

RECEIVED

APR 02 2003

TECH CENTER 1600/2900

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in an International Search Report of the European Patent Office in the corresponding patent application.

A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

Respectfully Submitted,

Date: 3-19-2003

Ferris H. Lander  
Ferris H. Lander  
Reg. No. 43,377  
McHale & Slavin, P.A.  
4440 PGA Boulevard, Suite 402  
Palm Beach Gardens, FL 33410  
Telephone: (561) 625-6575



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.

INVENTION: : APOLIPOPROTEIN BIOPOLYMER MARKER  
INDICATIVE OF NORMAL HUMAN

SERIAL NUMBER : 09/993,300

FILING DATE : November 23, 2001

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1741

ATTORNEY DOCKET NO. : 2132.107

RECEIVED  
MAR 28 2003  
TC 1700

CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e)

CERTIFICATE UNDER 37 CFR 1.8(a)  
I hereby certify that this correspondence is being  
deposited with the U.S. Postal Service as First Class mail  
in an envelope addressed to Commissioner for  
Patents, Washington, D.C. 20231 on 3-2003

Susan Bess

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §1.97(e), Applicants hereby certify that each item of information contained in the accompanying Supplemental Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office, namely an International Search Report for a counterpart European patent application, not more than three months prior to the filing of the accompanying Supplemental Information Disclosure Statement.

Accordingly, pursuant to 37 C.F.R. §1.97(e), Applicants request consideration and entry of the Supplemental Information Disclosure Statement.

Respectfully Submitted,

Date: 3-19-2003

Ferris H. Lander  
Ferris H. Lander  
Reg. No. 43,377  
McHale & Slavin, P.A.  
4440 PGA Boulevard, Suite 402  
Palm Beach Gardens, FL 33410  
Telephone: (561) 625-6575



Sheet 1 of 1

<b>Form PTO-1449</b> (Rev. 2-88)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
	ATTY. DOCKET NO. <b>2132.107</b>	APPLICATION NO. <b>09/993,300</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
<i>(Use several sheets if necessary)</i>			
APPLICANT <b>JACKOWSKI et al.</b>		FILING DATE <b>11/23/01</b>	GROUP <b>1741</b>

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use several sheets if necessary)*

## **U.S. PATENT DOCUMENTS**

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,033,862	03/00	Matsuda et al.			<i>RECEIVED MAR 28 2000</i>
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
✓ 0 770 875	05/97	Europe			<b>RECEIVED</b>	
					APR 02 2003	
					TECH CENTER 1600/2000	

**OTHER DOCUMENTS** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)**

		✓ Jungblut, et al., "Proteomics in human disease: Cancer, heart and infectious diseases", Electrophoresis (1999) Vol. 20, No. 10, pp. 2100-2110.
		✓ Kim, et al, "The reduction of NADH Ubiquinone oxidoreductase 24-and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease", Life Sciences (2001) Vo. 68, No. 24, pp. 2741-2750.
		✓ Finan, et al., "The complete sequence of the 1,683-kb pSymB megaplasmid from the N <sub>2</sub> -fixing and endosymbiont Sinorhizobium meliloti", Proceedings of the National Academy of Sciences of the United States (2001) Vol. 98, No. 17, pp. 9889-9894.
		✓ Database Swissprot 'Online! Retrieved from EBI (2000) accession no. Q9N3X8; XP-002232170.
		✓ Colwell, "Multifactorial Aspects of the Treatment of the Type II Diabetic Patient", Clinical and Experimental (1997), Vol. 46, No. 12, Supp 1, pp. 1-4.

**EXAMINER**

**DATE CONSIDERED**

- \* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.